Early Psychosis Clinical Trial
Official title:
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis: Understanding the Mechanism and Mediators of Action
This is an outpatient, single center, between-group, double blind, placebo controlled design. Approximately 120 adolescents and adult patients will be randomized to either have their treatment augmented with Cannabidiol Oral Solution (CBD) or with a matching CBD placebo for 8 weeks. The study will examine CBD as an augmentation strategy in early psychosis. It is hypothesized that CBD will improve symptoms, neurocognition, markers of inflammation and eating behaviors. Importantly, moderators and mediators of the CBD effects will be explored.
Participants will be randomly assigned in a 1:1 ratio to receive CBD or matching Placebo as an add-on to antipsychotic medication in an 8 week double blind trial. In this study, Cannabidiol Oral Solution (CBD) product will be used. This product is manufactured and supplied by GW Pharmaceuticals. The formulation is a 100 mg/mL solution. The CBD compound will be dosed at 1000mg/day administered in two divided doses. The dose of CBD was selected based on previous controlled trials that demonstrate the efficacy of CBD in patients with schizophrenia. The maximum duration of the study from screening to follow up of outcomes and adverse events will be approximately 8 weeks. Participants will receive either the CBD or placebo within this eight.weeks and will also complete pre-treatment, midpoint (week 4) and post-treatment testing (week 8). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06032182 -
PSYCHE Cognitive Remediation & Social Recovery Study
|
N/A | |
| Active, not recruiting |
NCT06192602 -
Effects of an Acceptance-based Medication Adherence Therapy for Recent-onset Psychosis
|
N/A | |
| Completed |
NCT04592042 -
Intervention to Improve Coping With Negative Emotions in Patients With Psychosis (Feel-Good-Study)
|
Early Phase 1 | |
| Completed |
NCT04373590 -
Decision-making and Decision Support Among Emerging Adults With First Episode Psychosis
|
N/A | |
| Active, not recruiting |
NCT04166019 -
Effect of a Peer-led Self-management Program for Recent-onset Psychosis
|
N/A | |
| Recruiting |
NCT04317807 -
R33: Levetiracetam in Early Psychosis
|
Phase 2 |